Overview

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Status:
Completed
Trial end date:
2012-09-11
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC